Vertex Pharmaceuticals Inc. said Monday that Canadian regulators have given their approval to Kalydeco, a drug designed to treat some patients suffering from cystic fibrosis, a rare and often fatal genetic disease.

In January, Cambridge-based Vertex received a similar approval for the drug from the Food and Drug Administration in the United States. Kalydeco was approved by European regulators in July.